Emergent BioSolutions Inc. (EBS) stock
EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3074% below fair value
$5.61−0.20 (-3.44%)
Close on Nov 17, 2026Market cap $287.64MP/E –Yield –
Emergent BioSolutions revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Emergent BioSolutions's revenue for the twelve months ending Sep 30, 2026 was $649.10M, down 17.7% year over year. For fiscal 2025 it was $742.90M, down 28.8% from the year before. Over ten years it grew 4.3% a year on average. The highest annual figure on record is $1.77B in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $742.90M | -28.8% |
| FY2024 | Dec 31, 2024 | $1.04B | -0.5% |
| FY2023 | Dec 31, 2023 | $1.05B | -6.1% |
| FY2022 | Dec 31, 2022 | $1.12B | -37.0% |
| FY2021 | Dec 31, 2021 | $1.77B | +12.4% |
| FY2020 | Dec 31, 2020 | $1.58B | +42.6% |
| FY2019 | Dec 31, 2019 | $1.11B | +41.4% |
| FY2018 | Dec 31, 2018 | $782.40M | +39.5% |
| FY2017 | Dec 31, 2017 | $560.90M | +14.8% |
| FY2016 | Dec 31, 2016 | $488.80M | -0.1% |
| FY2015 | Dec 31, 2015 | $489.33M | +21.0% |
| FY2014 | Dec 31, 2014 | $404.47M | +29.3% |
| FY2013 | Dec 31, 2013 | $312.75M | +10.9% |
| FY2012 | Dec 31, 2012 | $281.89M | +3.1% |
| FY2011 | Dec 31, 2011 | $273.38M | -4.5% |
| FY2010 | Dec 31, 2010 | $286.17M | +21.9% |
| FY2009 | Dec 31, 2009 | $234.79M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $110.00M | -52.4% |
| Q2 FY2026 | Jun 30, 2026 | $234.30M | +66.3% |
| Q1 FY2026 | Mar 31, 2026 | $156.10M | -29.7% |
| Q4 FY2025 | Dec 31, 2025 | $148.70M | -23.6% |
| Q3 FY2025 | Sep 30, 2025 | $231.10M | -21.3% |
| Q2 FY2025 | Jun 30, 2025 | $140.90M | -44.7% |
| Q1 FY2025 | Mar 31, 2025 | $222.20M | -26.0% |
| Q4 FY2024 | Dec 31, 2024 | $194.70M | -29.6% |
| Q3 FY2024 | Sep 30, 2024 | $293.80M | +8.6% |
| Q2 FY2024 | Jun 30, 2024 | $254.70M | -24.6% |
| Q1 FY2024 | Mar 31, 2024 | $300.40M | +82.8% |
| Q4 FY2023 | Dec 31, 2023 | $276.60M | -16.2% |
| Q3 FY2023 | Sep 30, 2023 | $270.50M | +12.8% |
| Q2 FY2023 | Jun 30, 2023 | $337.90M | +39.3% |
| Q1 FY2023 | Mar 31, 2023 | $164.30M | -46.1% |
| Q4 FY2022 | Dec 31, 2022 | $330.20M | -54.9% |
| Q3 FY2022 | Sep 30, 2022 | $239.90M | -16.2% |
| Q2 FY2022 | Jun 30, 2022 | $242.60M | -35.7% |
| Q1 FY2022 | Mar 31, 2022 | $304.80M | -19.2% |
| Q4 FY2021 | Dec 31, 2021 | $732.90M | +25.7% |
| Q3 FY2021 | Sep 30, 2021 | $286.30M | -25.7% |
| Q2 FY2021 | Jun 30, 2021 | $377.40M | -4.4% |
| Q1 FY2021 | Mar 31, 2021 | $377.00M | +95.8% |
| Q4 FY2020 | Dec 31, 2020 | $583.00M | +61.8% |
| Q3 FY2020 | Sep 30, 2020 | $385.20M | +23.5% |
| Q2 FY2020 | Jun 30, 2020 | $394.70M | +62.3% |
| Q1 FY2020 | Mar 31, 2020 | $192.50M | +1.0% |
| Q4 FY2019 | Dec 31, 2019 | $360.40M | +33.1% |
| Q3 FY2019 | Sep 30, 2019 | $311.80M | +79.5% |
| Q2 FY2019 | Jun 30, 2019 | $243.20M | +10.4% |
| Q1 FY2019 | Mar 31, 2019 | $190.60M | +61.8% |
| Q4 FY2018 | Dec 31, 2018 | $270.70M | +39.7% |
| Q3 FY2018 | Sep 30, 2018 | $173.70M | +16.3% |
| Q2 FY2018 | Jun 30, 2018 | $220.20M | +118.5% |
| Q1 FY2018 | Mar 31, 2018 | $117.80M | +0.8% |
| Q4 FY2017 | Dec 31, 2017 | $193.80M | +27.8% |
| Q3 FY2017 | Sep 30, 2017 | $149.40M | – |
| Q2 FY2017 | Jun 30, 2017 | $100.80M | – |
| Q1 FY2017 | Mar 31, 2017 | $116.90M | – |
| Q4 FY2016 | Dec 31, 2016 | $151.66M | – |
See a number that looks wrong?